Bayesian Cost-Effectiveness Analysis Using Individual-Level Data is Sensitive to the Choice of Uniform Priors on the Standard Deviations for Costs in Log-Normal Models [0.03%]
基于个体水平数据的贝叶斯成本效益分析对对数正态模型中成本标准差上的均匀先验的选择敏感
Xiaoxiao Ling,Andrea Gabrio,Gianluca Baio
Xiaoxiao Ling
Background: Bayesian cost-effectiveness analysis (CEA) requires the specification of prior distributions for all parameters to be empirically estimated via Bayes' rule. When costs are modelled via Log-Normal distributions...
Surrogate Outcomes Used as Proxies in Rare Long-Term Conditions: Evidence Assessment Group Perspective [0.03%]
罕见长期疾病条件下作为替代终点的代理指标：证据评估小组的观点
Eugenie Evelynne Johnson,Giovany Orozco-Leal,Aalya Al-Assaf et al.
Eugenie Evelynne Johnson et al.
Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCL [0.03%]
外部证据在外推中的作用及其政策影响的评估——以轴拉布妥珠单抗治疗二线DLBCL为例
Sam Harper,Daniela Afonso,Karina Watts et al.
Sam Harper et al.
Background and objective: Health technology assessment (HTA) of haemato-oncology therapies typically requires extrapolation of long-term survival beyond a trial's follow-up. Health technology assessment agencies must bala...
The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in Sweden [0.03%]
瑞典早期阿尔茨海默病患者使用莱卡内单抗的性价比评估研究
Xin Xia,Sandar Aye,Oskar Frisell et al.
Xin Xia et al.
Introduction: We sought to estimate the cost-effective price for lecanemab for treating early Alzheimer's disease in Sweden from the perspective of formal care payers. ...
Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity [0.03%]
肥胖症药物治疗的成本效益模型面临的挑战
Becky Pennington,Ewen Cummins,Albany Chandler et al.
Becky Pennington et al.
The cost effectiveness of pharmacotherapies for obesity (such as semaglutide, tirzepatide, liraglutide, and newer agents) is increasingly being appraised by health technology assessment (HTA) bodies. Modelling is required to extrapolate wei...
Challenges and Criteria for Single-Arm Trials Leading to an Added Benefit in German Health Technology Assessments [0.03%]
德国卫生技术评估中单臂试验的附加获益挑战及标准
Jörg Tomeczkowski,Tanja Heidbrede,Birte Eichinger et al.
Jörg Tomeczkowski et al.
Background: Randomized controlled trials are the standard for health technology assessment, but when they are infeasible or unethical, single-arm trials (SATs) are submitted. ...
Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART tool [0.03%]
化繁为简还是简而不失其要——基于健康经济决策模型的SMART工具研究
Teebah Abu-Zahra,Sabine E Grimm,Mirre Scholte et al.
Teebah Abu-Zahra et al.
Background: Developing health economic decision-analytic models requires making modelling choices to simplify reality while addressing the decision context. Finding the right balance between a decision-analytic model's si...
Microsimulation Modeling for Health Decision Sciences Using C++: A Tutorial [0.03%]
基于C++的健康决策科学微观模拟模型教程
Aku-Ville Lehtimäki,Janne Martikainen
Aku-Ville Lehtimäki
Microsimulation models have become increasingly common in the field of decision modeling for health. Because microsimulation models are computationally more demanding than traditional Markov cohort models, the use of computer programming la...
Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective [0.03%]
英国NICE技术评估中的成本比较：外部评估小组的视角
Marten J Poley,Nigel Armstrong,Huiqin Yang et al.
Marten J Poley et al.
Integrating Environmental Impact in Health Technology Assessment: An Exploratory Study [0.03%]
环境影响在卫生技术评估中的整合：一项探索性研究
Coline Ducrot,Julien Péron,Matthieu Delaye et al.
Coline Ducrot et al.
Objective: To what extent a care pathway, due to its associated pollution, may be more detrimental to future health than beneficial to contemporary patients is still an open question. We present a methodological framework...